Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Johanna C Bendell #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 6/x

RP2D 600mg Q3W
phase 1B ICI naive NSCLC cohort exp, 2 CRs
conclusion 1/2 https://t.co/KnT32HzjQA